Minerva Neurosciences reported $-7518000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -15.3M 28.41M
Adma Biologics ADMA:US $ -14.44M 1.14M
ALKERMES ALKS:US -19659000 24.08M
Arena Pharmaceuticals ARNA:US $ -194.48M 50.09M
AstraZeneca AZN:LN -1674000000 2.8B
Biocryst Pharmaceuticals BCRX:US $ -44.58M 15M
Bristol Myers Squibb BMY:US $ 1996M 281M
Dynavax Technologies DVAX:US $ 16.07M 12.13M
Eli Lilly And LLY:US $ 1476M 72.6M
Esperion Therapeutics ESPR:US $ -55745000 23.21M
GlaxoSmithKline GSK:LN 1.94B 263M
Halozyme Therapeutics HALO:US $ 75.59M 17.46M
Johnson & Johnson JNJ:US $ 3849M 2813M
Kindred Biosciences KIN:US -8544000 622K
Marinus Pharmaceuticals MRNS:US $ -19.17M 4.32M
Merk MRK:US $ 4826M 3212M
Minerva Neurosciences NERV:US $ -7.52M 1.44M
Neurocrine Biosciences NBIX:US $ 44.5M 18.3M
Novartis NOVN:VX 3.23B 246M
Novavax NVAX:US $ -307.14M 38.68M
Pfizer PFE:US $ 7647M 1733M
Takeda 4502:JP Y 97427M 151125M
Vanda Pharmaceuticals VNDA:US $ 10.82M 1.55M